{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:52:20Z","timestamp":1782993140890,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jocn.2014.03.019","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T21:17:14Z","timestamp":1405631834000},"page":"1909-1914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis"],"prefix":"10.1016","volume":"21","author":[{"given":"M.","family":"Nagappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Netravathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Taly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Bindu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2014.03.019_b0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V87.2.491.bloodjournal872491","article-title":"Complete remission in severe aplastic anaemia after high-dose cyclophosphamide without bone marrow transplantation","volume":"87","author":"Brodsky","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jocn.2014.03.019_b0010","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0140-6736(00)04278-1","article-title":"High-dose cyclophosphamide in aplastic anemia","volume":"357","author":"Brodsky","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.03.019_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u2018rebooting\u2019 with a high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.03.019_b0020","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocn.2014.03.019_b0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2014.03.019_b0030","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.03.019_b0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2014.03.019_b0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.880050115","article-title":"Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide","volume":"5","author":"Pestronk","year":"1982","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2014.03.019_b0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM197701202960301","article-title":"Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice","volume":"296","author":"Toyka","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.03.019_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0955-3886(97)00102-1","article-title":"Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide","volume":"19","author":"Flachenecker","year":"1998","journal-title":"Transfus Sci"},{"key":"10.1016\/j.jocn.2014.03.019_b0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.31.1.32","article-title":"Stable remissions in myasthenia gravis","volume":"31","author":"Perez","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.03.019_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2014.03.019_b0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/jnnp.2003.019232","article-title":"High dose cyclophosphamide for severe refractory myasthenia gravis","volume":"75","author":"Gladstone","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.03.019_b0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.03.019_b0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CND.0b013e31828ee913","article-title":"Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis","volume":"14","author":"Nagappa","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jocn.2014.03.019_b0080","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.03.019_b0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unraveling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jocn.2014.03.019_b0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","article-title":"High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies","volume":"33","author":"Lin","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2014.03.019_b0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.7326\/0003-4819-129-12-199812150-00007","article-title":"Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease","volume":"129","author":"Brodsky","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocn.2014.03.019_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01526181","article-title":"Complications of cyclophosphamide therapy","volume":"254","author":"Langford","year":"1997","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jocn.2014.03.019_b0105","doi-asserted-by":"crossref","unstructured":"de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150: 670\u201380.","DOI":"10.7326\/0003-4819-150-10-200905190-00004"},{"key":"10.1016\/j.jocn.2014.03.019_b0110","doi-asserted-by":"crossref","unstructured":"Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955\u201360.","DOI":"10.1136\/annrheumdis-2011-200477"},{"key":"10.1016\/j.jocn.2014.03.019_b0115","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood.V85.10.2742.bloodjournal85102742","article-title":"Assessment of aldehyde dehydrogenase in viable cells","volume":"85","author":"Jones","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jocn.2014.03.019_b0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/anr.1780320108","article-title":"Infectious complications of cyclophosphamide treatment for vasculitis","volume":"32","author":"Bradley","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocn.2014.03.019_b0125","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s00467-005-2032-4","article-title":"Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy","volume":"20","author":"Opastirakul","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jocn.2014.03.019_b0130","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780390906","article-title":"Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus","volume":"39","author":"Pryor","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocn.2014.03.019_b0135","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1212\/WNL.51.6.1735","article-title":"Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"Good","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.03.019_b0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758681400263X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758681400263X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T10:44:58Z","timestamp":1598093098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758681400263X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S096758681400263X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2014.03.019","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2014.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}